Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

Status Active, not recruiting

Clinical Trial Summary

Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached by multidisciplinary teams in high specialized centers. Until today no standard of care exists to treat these cancers. The identification of a target, the androgen receptor, in SG tumors has allowed for new treatment strategies options for this rare group of diseases. As a matter of fact, strong positivity for androgen expression has been found in salivary duct carcinoma and adenocarcinomas. The purpose of this study is therefore to evaluate the efficacy and safety of chemotherapy versus androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic AR expressing SGCs. The study will include two cohorts of patients: Cohort A, which comprises chemo-naïve patients, and Cohort B, which comprises pretreated patients.

Clinical Trial Description

Patients in Cohort A will be randomized 1:1 at the study entry to receive ADT (triptorelin + bicalutamide 50 mg) or standard chemotherapy. Patients of Cohort A randomized to the control arm (chemotherapy arm) will be given the option to enter Cohort B at the time of disease progression. As long as Cohort A is open to recruitment, patients who will be treated by chemotherapy will be simultaneously enrolled in Cohort B. Accrual in Cohort B will be stopped when recruitment of 76 eligible patients in Cohort A is reached. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01969578
Study type	Interventional
Source	European Organisation for Research and Treatment of Cancer - EORTC
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	September 24, 2015
Completion date	July 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03729297` - Cabozantinib in Advanced Salivary Gland Cancer Patients	Phase 2
Completed	`NCT01703455` - Activity of Sorafenib in Salivary Gland Cancer	Phase 2
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Active, not recruiting	`NCT05010629` - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma	Phase 2
Active, not recruiting	`NCT03781986` - APG-115 in Salivary Gland Cancer Trial	Phase 1/Phase 2
Completed	`NCT03319641` - PSMA-PET Imaging for Advanced ACC/SDC	N/A
Recruiting	`NCT02012699` - Integrated Cancer Repository for Cancer Research
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting	`NCT05483374` - The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
Completed	`NCT04291300` - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients	Phase 2
Active, not recruiting	`NCT03172624` - Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer	Phase 2
Completed	`NCT00509002` - Iressa Study in Patients With Salivary Gland Cancer	Phase 2
Active, not recruiting	`NCT05008237` - Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study	Phase 2
Recruiting	`NCT03360890` - Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors	Phase 2
Not yet recruiting	`NCT05898373` - Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC	Phase 1/Phase 2
Active, not recruiting	`NCT02069730` - A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes	N/A
Recruiting	`NCT04209660` - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers	Phase 2
Completed	`NCT01344356` - Stereotactic Body Radiotherapy for Head and Neck Tumors	Phase 4
Completed	`NCT03602079` - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene	Phase 1/Phase 2
Not yet recruiting	`NCT06091878` - Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers